Eagle Pharmaceuticals(EGRX) - 2022 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In Q4 2022, adjusted non-GAAP earnings per diluted share was $1.10, up from $0.83 in Q4 2021, representing a 32.5% increase [6] - Full-year 2022 adjusted non-GAAP earnings per diluted share was $7.79, more than tripling from $1.68 in 2021 [26] - Total revenue for full-year 2022 was $316.6 million, compared to $171.5 million in 2021 [56] - Net income for Q4 2022 was $8.2 million or $0.63 per basic share, compared to a net loss of $6.2 million in Q4 2021 [41] Business Line Data and Key Metrics Changes - PEMFEXY net sales reached $67 million in 2022, with Q4 sales of $12 million and a market share of 6% in community oncology [8][29] - Bendamustine franchise revenue grew in 2022, with BELRAPZO and TREAKISYM net revenues increasing by 42% and 97% respectively, while BENDEKA saw a decline [9] - Combined sales of BARHEMSYS and BYFAVO in the second half of 2022 were nearly $1.5 million, doubling from $722,000 in the same period of 2021 [11] Market Data and Key Metrics Changes - The company holds an 88% share of the U.S. bendamustine market with BENDEKA and BELRAPZO, historically maintaining about a 90% share [30] - The gross margin for Q4 2022 was 67%, down from 71% in the prior year, due to the addition of lower-margin products [58] Company Strategy and Development Direction - The company aims to make an accretive acquisition to solidify growth and is focused on developing important products while maintaining profitability [28][33] - The pipeline includes ENA-001, a new chemical entity for treating respiratory depression, and CAL02, an anti-virulence agent for pneumonia [13][34] - The company plans to balance clinical development and acquisitions, recognizing the risks and potential returns of each [35] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in maintaining strong profitability and expects adjusted non-GAAP EBITDA of $74 million to $80 million for 2023 [28] - The company is optimistic about the growth of PEMFEXY and the overall product line, anticipating a strong year ahead [15][68] - Management noted the decision to exit the vasopressin market due to strong performance in other areas and the crowded nature of the generic market [17][54] Other Important Information - The company had $55.3 million in cash and cash equivalents and $72.4 million in net accounts receivable as of December 31, 2022 [43] - R&D expenses for full-year 2022 were $34.1 million, down from $51.3 million in 2021, reflecting lower costs associated with prior agreements [59] - SG&A expenses for full-year 2022 were $106.6 million, up from $75.3 million in 2021, primarily due to the acquisition of Acacia [60] Q&A Session Summary Question: Can you discuss the growth expectations for PEMFEXY? - Management indicated that they expect to grow market share from 10% to 12% by the end of March 2023 and anticipate sales exceeding last year's $67 million [67][68] Question: What are the considerations behind the withdrawal from the vasopressin market? - Management explained that the decision was based on the strength of their other products and the crowded nature of the vasopressin market, indicating no plans to return in the near future [54][78] Question: How do you view the long-term market share for BENDEKA and BELRAPZO? - Management expressed confidence in maintaining approximately 75% of gross profit from these products in 2023, noting strong performance despite new competition [31][73]